Hepatitis C and renal transplantation in era of new antiviral agents

Table 5 American Association for the Study of Liver Diseases Recommendation for treating hepatitis C virus in patients with renal impairment

Recommended	Rating	Genotype	Duration
Recommendations for patients with CKD stage 1, 2 or 3
No dose adjustment is required when using (1) Daclatasvir (60 mg) (2) Daily fixed-dose combination of elbasvir (50 mg)/grazopevir (100 mg) (3) Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) (4) Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) (5) Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) (6) Simeprevir (150 mg) (7) Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) (8) Sofosbuvir (400 mg)	I, A
Recommendations for patients with CKD stage 4 or 5 (eGFR < 30 mL/min or ESRD
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	I, B	1a, 1b, 4	12 wk
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)	I, B	1, 2, 3, 4, 5, 6	8 to 16 wk

CKD: Chronic kidney disease; ESRD: End-stage renal disease.